ArticleWorld journal of surgical oncology2013
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
Article in World journal of surgical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.Breast cancer research and treatment · 2025Article
- Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breast.The oncologist · 2025Article
- Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.Frontiers in medicine · 2025Article
- Primary Neuroendocrine Tumor of the Breast: A Case Report and Review of Current Guidelines.Cureus · 2024Article
- Neuroendocrine neoplasms of the breast: a review of literature.Virchows Archiv : an international journal of pathology · 2024Review
- Non-metastatic primary neuroendocrine neoplasms of the breast: a reference cancer center's experience of a heterogenous entity.Frontiers in endocrinology · 2024Article
- Management of Neuroendocrine Breast Carcinoma (NEBC): Review of Literature.Oncology reviews · 2024Review
- The Approach of Artificial Intelligence in Neuroendocrine Carcinomas of the Breast: A Next Step towards Precision Pathology?-A Case Report and Review of the Literature.Medicina (Kaunas, Lithuania) · 2023Review
- Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.Frontiers in endocrinology · 2023Article
- Primary Breast Neuroendocrine Tumors: An Analysis of the National Cancer Database.Annals of surgical oncology · 2022Article
- Primary neuroendocrine tumors of the breast: About a case and of the review of the literature.International journal of surgery case reports · 2022Article
- Primary neuroendocrine carcinoma of the breast with leptomeninges metastasis: A case report and literature review.The Journal of international medical research · 2022Review
- Prognostic factors of primary neuroendocrine breast cancer: A population-based study.Cancer medicine · 2022Article
- Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types.Frontiers in medicine · 2022Article
- Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.Cancers · 2021Review
- Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021Review
- Primary neuroendocrine carcinoma of the breast: a rare presentation and review of the literature.Intractable & rare diseases research · 2020Article
- Rare Human Epidermal Growth Factor Receptor 2 (HER-2)-Positive Neuroendocrine Carcinoma of the Breast: A Case Report with 9-Year Follow-up.The American journal of case reports · 2020Article
- Neuroendocrine breast carcinoma: a rare but challenging entity.Medical oncology (Northwood, London, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary neuroendocrine carcinoma of the breast is a heterogeneous group of rare tumors with positive immunoreactivity to neuroendocrine markers in at least 50% of cells. Diagnosis also requires that other primary sites be ruled out and that the same tumor show histological evidence of a breast in situ component. Primary neuroendocrine carcinoma of the breast rarely presents as locally advanced disease and less frequently with such widespread metastatic disease as described herein. The review accompanying this case report is the first to provide an overview of all the cases of primary neuroendocrine carcinoma of the breast published in the literature and encompasses detailed information regarding epidemiology, histogenesis, clinical and histologic diagnosis criteria, classification, surgical and adjuvant treatment, as well as prognosis. We also provide recommendations for common clinical and histologic pitfalls associated with this tumor. CASE PRESENTATION: We describe a case of a 51-year-old Hispanic woman initially diagnosed with locally-advanced invasive ductal carcinoma that did not respond to neoadjuvant treatment. After undergoing modified radical mastectomy the final surgical pathology showed evidence of alveolar-type primary neuroendocrine carcinoma of the breast. The patient was treated with cisplatin/etoposide followed by paclitaxel/carboplatinum. Thirteen months after surgery the patient is alive, but developed pulmonary, bone, and hepatic metastasis.
conclusionThe breast in situ component of primary neuroendocrine carcinoma of the breast may prevail on a core biopsy samples increasing the probability of underdiagnosing this tumor preoperatively. Being aware of the existence of this disease allows for timely diagnosis and management. Optimal treatment requires simultaneous consideration of both the neuroendocrine and breast in situ tumor features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.